483 related articles for article (PubMed ID: 24136935)
21. Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer.
Heijmen L; ter Voert EE; Oyen WJ; Punt CJ; van Spronsen DJ; Heerschap A; de Geus-Oei LF; van Laarhoven HW
PLoS One; 2015; 10(4):e0120823. PubMed ID: 25831053
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
[TBL] [Abstract][Full Text] [Related]
23. Improved long-term survival after resection of colorectal liver metastases following staging with FDG positron emission tomography.
Abbadi RA; Sadat U; Jah A; Praseedom RK; Jamieson NV; Cheow HK; Whitley S; Ford HE; Wilson CB; Harper SJ; Huguet EL
J Surg Oncol; 2014 Sep; 110(3):313-9. PubMed ID: 24737685
[TBL] [Abstract][Full Text] [Related]
24. Comparison of EORTC criteria and PERCIST for PET/CT response evaluation of patients with metastatic colorectal cancer treated with irinotecan and cetuximab.
Skougaard K; Nielsen D; Jensen BV; Hendel HW
J Nucl Med; 2013 Jul; 54(7):1026-31. PubMed ID: 23572497
[TBL] [Abstract][Full Text] [Related]
25. Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor.
Egger ME; Cannon RM; Metzger TL; Nowacki M; Kelly L; Tatum C; Scoggins CR; Callender GG; McMasters KM; Martin RC
J Am Coll Surg; 2013 Apr; 216(4):845-56; discussion 856-7. PubMed ID: 23415549
[TBL] [Abstract][Full Text] [Related]
26. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery.
Wiering B; Ruers TJ; Krabbe PF; Dekker HM; Oyen WJ
Ann Surg Oncol; 2007 Feb; 14(2):818-26. PubMed ID: 17136470
[TBL] [Abstract][Full Text] [Related]
27. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive role of [
Zucali PA; Lopci E; Ceresoli GL; Giordano L; Perrino M; Ciocia G; Gianoncelli L; Lorenzi E; Simonelli M; De Vincenzo F; Setti LR; Bonifacio C; Bonomi M; Bombardieri E; Chiti A; Santoro A
Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
[TBL] [Abstract][Full Text] [Related]
29. Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.
Roedl JB; Colen RR; Holalkere NS; Fischman AJ; Choi NC; Blake MA
Radiother Oncol; 2008 Dec; 89(3):278-86. PubMed ID: 18701180
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
[TBL] [Abstract][Full Text] [Related]
31. Early prediction by 18F-FDG PET/CT for progression-free survival and overall survival in patients with metastatic colorectal cancer receiving third-line cetuximab-based therapy.
Liu FY; Yen TC; Wang JY; Yang TS
Clin Nucl Med; 2015 Mar; 40(3):200-5. PubMed ID: 25608159
[TBL] [Abstract][Full Text] [Related]
32. Computer-aided detection (CAD) and assessment of malignant lesions in the liver and lung using a novel PET/CT software tool: initial results.
Hahn S; Heusner T; Zhou X; Zhan Y; Peng Z; Hamami M; Forsting M; Bockisch A; Antoch G
Rofo; 2010 Mar; 182(3):243-7. PubMed ID: 19859858
[TBL] [Abstract][Full Text] [Related]
33. The role of routine clinical pretreatment 18F-FDG PET/CT in predicting outcome of colorectal liver metastasis.
Tam HH; Cook GJ; Chau I; Drake B; Zerizer I; Du Y; Cunningham D; Koh DM; Chua SS
Clin Nucl Med; 2015 May; 40(5):e259-64. PubMed ID: 25742225
[TBL] [Abstract][Full Text] [Related]
34. Surrogate Imaging Biomarkers of Response of Colorectal Liver Metastases After Salvage Radioembolization Using 90Y-Loaded Resin Microspheres.
Shady W; Sotirchos VS; Do RK; Pandit-Taskar N; Carrasquillo JA; Gonen M; Sofocleous CT
AJR Am J Roentgenol; 2016 Sep; 207(3):661-70. PubMed ID: 27384594
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer.
Soydal C; Kucuk ON; Gecim EI; Bilgic S; Elhan AH
Nucl Med Commun; 2013 May; 34(5):501-6. PubMed ID: 23478586
[TBL] [Abstract][Full Text] [Related]
36. Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: value of FDG PET versus computed tomography.
Szyszko T; Al-Nahhas A; Canelo R; Habib N; Jiao L; Wasan H; Pagou M; Tait P
Nucl Med Commun; 2007 Jan; 28(1):15-20. PubMed ID: 17159544
[TBL] [Abstract][Full Text] [Related]
37. Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.
Dohan A; Gallix B; Guiu B; Le Malicot K; Reinhold C; Soyer P; Bennouna J; Ghiringhelli F; Barbier E; Boige V; Taieb J; Bouché O; François E; Phelip JM; Borel C; Faroux R; Seitz JF; Jacquot S; Ben Abdelghani M; Khemissa-Akouz F; Genet D; Jouve JL; Rinaldi Y; Desseigne F; Texereau P; Suc E; Lepage C; Aparicio T; Hoeffel C;
Gut; 2020 Mar; 69(3):531-539. PubMed ID: 31101691
[TBL] [Abstract][Full Text] [Related]
38. FDG-PET-CT is effective in selecting patients with poor long term survivals for colorectal liver metastases.
Yip VS; Poston GJ; Fenwick SW; Wieshmann H; Athwal T; Malik HZ
Eur J Surg Oncol; 2014 Aug; 40(8):995-9. PubMed ID: 24290370
[TBL] [Abstract][Full Text] [Related]
39. Performance of tumor growth kinetics as an imaging biomarker for response assessment in colorectal liver metastases: correlation with FDG PET.
Seyal AR; Parekh K; Arslanoglu A; Gonzalez-Guindalini FD; Tochetto SM; Velichko YS; Yaghmai V
Abdom Imaging; 2015 Oct; 40(8):3043-51. PubMed ID: 26353898
[TBL] [Abstract][Full Text] [Related]
40. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
